Robert M. Janosky
Corporate Officer/Principal bij SATSUMA PHARMACEUTICALS, INC.
Actieve functies van Robert M. Janosky
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05-03-2020 | - |
Loopbaan van Robert M. Janosky
Eerdere bekende functies van Robert M. Janosky
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| DURECT CORPORATION | Corporate Officer/Principal | 01-01-2016 | 01-03-2020 |
Opleiding van Robert M. Janosky
| University of Vermont | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Beurs
- Insiders
- Robert M. Janosky
- Ervaring
